Future strategies in hematopoietic stem cell transplantation for rheumatoid arthritis

Journal of Rheumatology

Volumn 28, Issue SUPPL. 64, 2001, Pages 42-48

  Burt, R K ^a   Barr, W ^a   Oyama, Y ^a   Traynor, A ^a   Slavin, S ^a  

^a Division of Immunotherapy   (United States)

Author keywords

Hematopoietic stem cell transplantation; Rheumatoid arthritis

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; AUTOIMMUNE DISEASE; CONFERENCE PAPER; DRUG INDUCED DISEASE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATION; MORTALITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ARTICLE; AUTOTRANSPLANTATION; CLINICAL TRIAL; FORECASTING; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY;

ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; FORECASTING; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0034795530     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (71)

1. Bone marrow transplantation in patients with gold-induced marrow aplasia
2. Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anaemia
3. Apparent cure of rheumatoid arthritis by bone marrow transplantation
4. Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year followup
5. Non-articular complications of rheumatoid arthritis
6. Rheumatoid arthritis: Extra-articular manifestations II
7. HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes
8. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
9. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region
10. HLA and rheumatoid arthritis
11. Molecular mimicry and autoimmunity
12. Regression and spreading of self-recognition during the development of autoimmune demyelinating disease
13. The functional significance of epitope spreading and its regulation by co-stimulatory molecules
14. Epitope spreading
15. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen
16. Animal models of rheumatoid arthritis
17. Collagen-induced arthritis, an animal model of autoimmunity
18. A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats
19. Identification of four new quantitative trait loci regulating arthritis severity and one new quantitative trait locus regulating autoantibody production in rats with collagen-induced arthritis
20. Genetic factors regulating experimental arthritis in mice and rats
21. Protooncogenes and autoimmunity
22. Treatment of life threatening autoimmune diseases with myeloablative doses of immunosuppressive agents and autologous bone marrow transplantation - Rationale and experimental background
23. Stem cell transplantation in experimental models of autoimmune disease
24. Conditioning regimens for the treatment of experimental arthritis with autologous bone marrow transplantation
25. Effective treatment of mice with type II collagen induced arthritis with lethal irradiation and bone marrow transplantation
26. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: Two cellular mechanisms explain joint destruction?
27. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: Passive responders or transformed aggressors?
28. Dominant-negative p53 mutations in rheumatoid arthritis
29. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium
30. Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue
31. Rheumatoid factor isotype switch and somatic mutation variants within rheumatoid arthritis synovium
32. T cell receptor repertoire in rheumatoid arthritis
33. TCR beta spectratyping in RA: Evidence of clonal expansions in peripheral blood lymphocytes
34. Mortality in the rheumatic diseases
35. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures
36. Survival, prognosis, and causes of death in rheumatoid arthritis
37. Mortality predictors among 263 patients with rheumatoid arthritis
38. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis
39. Length of life and cause of death in rheumatoid arthritis
40. Mortality in rheumatoid arthritis
41. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis
42. Survival, prognosis, and causes of death in rheumatoid arthritis
43. Survival and cause of death in rheumatoid arthritis: A 25-year prospective followup
44. Survivorship and death in rheumatoid arthritis
45. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation
46. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy
47. Remission of nonerosive polyarthritis associated with Sjogren's syndrome after autologous hematopoietic stem cell transplantation for lymphoma
48. Autologous bone-marrow transplantation for rheumatoid arthritis
49. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis: Sustained response in two of four patients
50. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis
51. Remission and immune reconstitution after T-cell-depleted stem-cell transplantation for rheumatoid arthritis
52. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation
53. High-dose chemotherapy and syngeneic hemopoietic stem-cell transplantation for severe, seronegative rheumatoid arthritis
54. Autologous blood stem cell transplantation can overcome and modulate therapeutic resistance in severe rheumatoid arthritis
55. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
56. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis
57. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
58. Graft-versus-leukemia reactions after bone marrow transplantation
59. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man
60. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation
61. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes
62. Immunotherapy of leukemia in conjunction with non-myeloablative conditioning: Engraftment of blood stem cells and eradication of host leukemia with nonmyeloablative conditioning based on Fludarabine and anti-thymocyte globulin
63. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-vs-leukemia without myeloablative therapy
64. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
65. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis - Lessons from Hodgkin's disease and coronary artery disease
66. Anticytokine therapy - A new era in the treatment of rheumatoid arthritis?
67. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
68. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor versus placebo in rheumatoid arthritis
69. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
70. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease
71. Risk of donor lymphocyte infusions following allogeneic bone marrow transplantation